Allogene Therapeutics, Inc. 4

Douglas Earl Martin, SVP and General Counsel of Allogene Therapeutics, Inc. (ALLO), sold 29,697 shares of common stock at $2.12 per share in a mandatory sell-to-cover transaction related to RSU vesting.

On August 21, 2026, Douglas Earl Martin, SVP and General Counsel of Allogene Therapeutics, Inc., executed a mandatory sell-to-cover transaction in which 29,697 shares of common stock were sold at an average price of $2.12 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units, reducing his direct holdings to 488,267 shares. The filing notes that this sale was not a discretionary trade but was required under the company’s equity incentive plan. The footnotes also disclose the forfeiture of 54,479 performance-based RSUs previously granted on August 14, 2023, and prior acquisition of 7,495 shares through an employee stock purchase program, though these items do not appear as separate line-item transactions in this Form 4.

Filing Facts

CIK

1737287

Ticker

ALLO

Form

4

Source Type

fda

Accession

0001628280-26-058920

Alert Tier

5